Pure Biologics Spólka Akcyjna - Asset Resilience Ratio

Latest as of September 2023: 6.13%

Pure Biologics Spólka Akcyjna (PUR) has an Asset Resilience Ratio of 6.13% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

zł3.99 Million

≈ $1.10 Million USD Cash + Short-term Investments

Total Assets

zł65.18 Million

≈ $17.94 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2022)

This chart shows how Pure Biologics Spólka Akcyjna's Asset Resilience Ratio has changed over time. Check PUR PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Pure Biologics Spólka Akcyjna's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Pure Biologics Spólka Akcyjna stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	zł0.00	0%
Short-term Investments	zł3.99 Million	6.13%
Total Liquid Assets	zł3.99 Million	6.13%

Asset Resilience Insights

Limited Liquidity: Pure Biologics Spólka Akcyjna maintains only 6.13% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Pure Biologics Spólka Akcyjna Industry Peers by Asset Resilience Ratio

Compare Pure Biologics Spólka Akcyjna's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%

Annual Asset Resilience Ratio for Pure Biologics Spólka Akcyjna (2021–2022)

The table below shows the annual Asset Resilience Ratio data for Pure Biologics Spólka Akcyjna.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	14.90%	zł4.92 Million ≈ $1.35 Million	zł33.01 Million ≈ $9.08 Million	-41.79pp
2021-12-31	56.69%	zł26.75 Million ≈ $7.36 Million	zł47.19 Million ≈ $12.99 Million	--

pp = percentage points

About Pure Biologics Spólka Akcyjna

WAR:PUR Poland Biotechnology

Market Cap

$8.76 Million

zł31.84 Million PLN

Market Cap Rank

#27386 Global

#297 in Poland

Share Price

zł2.81

Change (1 day)

+26.01%

52-Week Range

zł1.42 - zł7.70

All Time High

zł142.00